Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
NCT04885634 on ClinicalTrials.gov · last registry update 2023-11-03
Withdrawn before anyone was enrolled. Its estimated completion date, January 2024, has passed with no update to the record. Primary outcome, as filed: Number of Participants to Complete Recruitment. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for atrial fibrillation — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- WITHDRAWN
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Axel Brandes
- Sponsor type
- Other
- Enrollment
- 0
- Started
- 2022-10
- Primary completion
- 2024-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of Participants to Complete Recruitment
Conditions studied
Atrial Fibrillation · Overweight and Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.